Weil advised the underwriters in connection with Zimmer Biomet Holdings, Inc.’s $1.75 billion notes offering, consisting of its (i) $600 million aggregate principal amount of 4.700% notes due 2027, (ii) $550 million aggregate principal amount of 5.050% notes due 2030 and (iii) $600 million aggregate principal amount of 5.500% notes due 2035. The proceeds will be used for the Paragon 28 merger and any remaining amounts will be used for general corporate purposes, including repayment of indebtedness. Founded in 1927, Zimmer Biomet is a global medical technology leader offering innovative implants and digital technologies across all stages of the patient journey.

The Weil deal team was led by Capital Markets Co-Head Michael Hickey and included Capital Markets associates Michael Cremers, Zachary Fialkow and Alex Hansen; Tax partner Graham Magill and associate Madeline Joerg; and Regulatory partner Timothy Welch.